Zoledronsyra STADA: Uses, Dosage & Side Effects
A potent bisphosphonate infusion used to prevent skeletal complications from bone metastases and to treat tumor-induced hypercalcemia
Zoledronsyra STADA (zoledronic acid) is a third-generation bisphosphonate administered as an intravenous infusion. It is one of the most potent inhibitors of osteoclast-mediated bone resorption available. In oncology, the 4 mg formulation is used to prevent skeletal-related events (pathological fractures, spinal cord compression, need for bone radiation or surgery) in patients with bone metastases from solid tumors, and to lower dangerously elevated calcium levels in tumor-induced hypercalcemia (TIH). Zoledronic acid is listed on the WHO Model List of Essential Medicines and has been shown in landmark clinical trials to significantly reduce skeletal morbidity in patients with advanced cancer. A separate 5 mg formulation is used for the treatment of osteoporosis and Paget’s disease.
Quick Facts: Zoledronsyra STADA
Key Takeaways
- Zoledronic acid is a highly potent bisphosphonate given as a 15-minute intravenous infusion, primarily used in oncology to prevent bone complications from cancer metastases.
- The standard oncology dose is 4 mg every 3–4 weeks; dose reduction is required in patients with mild to moderate kidney impairment (creatinine clearance 30–60 ml/min).
- Adequate hydration before and after infusion is critical to protect kidney function; renal parameters must be checked before each dose.
- Osteonecrosis of the jaw (ONJ) is an uncommon but serious risk — a dental examination is recommended before starting treatment, and invasive dental procedures should be avoided during therapy.
- Flu-like symptoms (fever, bone and muscle pain, fatigue) are very common after the first infusion but typically resolve within 1–3 days and diminish with subsequent treatments.
What Is Zoledronic Acid and What Is It Used For?
Zoledronic acid belongs to the bisphosphonate class of medications — drugs that bind tightly to the mineral matrix of bone and inhibit the cells responsible for bone breakdown (osteoclasts). Among the bisphosphonates, zoledronic acid is the most potent available agent, with an estimated 100–850 times greater potency than pamidronate and approximately 10,000 times greater potency than etidronate in preclinical models. This exceptional potency allows effective bone protection with a relatively small dose given as a brief intravenous infusion.
The mechanism of action involves inhibition of farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway within osteoclasts. By blocking this enzyme, zoledronic acid disrupts several cellular processes essential for osteoclast function and survival, including protein prenylation, cytoskeletal organization, and cell signaling. This leads to osteoclast apoptosis (programmed cell death) and a marked reduction in bone resorption. The net effect is a significant decrease in bone turnover markers and a reduction in skeletal complications.
In the oncology setting, the 4 mg formulation of zoledronic acid is used for two primary indications:
- Prevention of skeletal-related events (SREs) in adults with bone metastases from solid tumors. Bone metastases are a common complication of advanced cancers, particularly breast cancer, prostate cancer, and lung cancer. They cause accelerated bone destruction, leading to pathological fractures, spinal cord compression, severe pain, and the need for radiation therapy or surgery. By inhibiting osteoclast activity, zoledronic acid slows this destructive process and reduces the incidence of these complications.
- Treatment of tumor-induced hypercalcemia (TIH). Certain malignant tumors can accelerate bone resorption to such an extent that calcium is released from bone faster than the kidneys can excrete it, resulting in dangerously elevated blood calcium levels. Symptoms of TIH include nausea, vomiting, confusion, lethargy, cardiac arrhythmias, and potentially coma and death. Zoledronic acid rapidly reduces serum calcium by inhibiting osteoclast-mediated bone resorption.
The landmark phase III clinical trials (the Zometa International Study, published in Cancer, 2003) demonstrated that zoledronic acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal-related event compared with placebo, and extended the median time to the first SRE. In breast cancer patients with bone metastases, zoledronic acid reduced the overall risk of skeletal events by approximately 36% and delayed the median time to the first skeletal event from 12 to over 16 months.
A separate 5 mg formulation of zoledronic acid (given as an annual infusion) is used for the treatment of postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, and Paget’s disease of bone. While the active ingredient is the same, these formulations are dosed differently and used for distinct clinical indications. This article focuses primarily on the 4 mg oncology formulation, although much of the safety and precautionary information applies to both formulations.
What Should You Know Before Receiving Zoledronic Acid?
Zoledronic acid is a powerful medication that requires careful patient selection and monitoring. Before starting treatment, your healthcare team will conduct blood tests to evaluate your kidney function and electrolyte levels, particularly calcium, phosphate, and magnesium. These parameters must be within acceptable ranges before the first infusion, and they will be monitored regularly throughout the course of treatment.
Contraindications
You should not receive zoledronic acid if any of the following apply:
- You are allergic to zoledronic acid, other bisphosphonates, or any of the other ingredients (mannitol, sodium citrate)
- You are currently breastfeeding
- You have severe kidney impairment (creatinine clearance below 30 ml/min) — for bone metastases treatment
- You have uncorrected hypocalcemia (low blood calcium) that has not been treated
Warnings and Precautions
Talk to your doctor before receiving zoledronic acid if any of the following conditions apply:
- Kidney disease — current or past kidney problems require careful evaluation, as zoledronic acid is eliminated by the kidneys and can cause renal impairment, especially if administered too rapidly
- Jaw problems — pain, swelling, numbness, a feeling of heaviness in the jaw, or a loose tooth may indicate osteonecrosis of the jaw (ONJ), a rare but serious condition
- Dental procedures — inform your dentist that you are receiving zoledronic acid treatment; invasive dental procedures may increase the risk of ONJ
- Low calcium levels — existing hypocalcemia must be corrected before starting treatment with adequate calcium and vitamin D supplementation
A dental examination is recommended before you start treatment with zoledronic acid. Maintain good oral hygiene (including regular brushing) and attend regular dental check-ups throughout treatment. Contact your doctor and dentist immediately if you experience problems with your mouth or teeth such as loose teeth, pain or swelling, non-healing sores, or discharge, as these may be signs of ONJ. Patients undergoing chemotherapy, radiotherapy, taking corticosteroids, undergoing dental surgery, with poor dental health, or who smoke have a higher risk of developing this condition. The use of anti-angiogenic agents in combination with zoledronic acid has also been associated with an increased risk of ONJ.
Decreased calcium levels in the blood (hypocalcemia) have been reported in patients treated with zoledronic acid and can sometimes lead to muscle cramps, dry skin, and a burning sensation. Irregular heartbeat (cardiac arrhythmia), seizures, spasms, and twitching (tetany) have been reported as a result of severe hypocalcemia. In some cases, hypocalcemia can be life-threatening. If any of these symptoms occur, contact your doctor immediately. Your healthcare team will prescribe calcium and vitamin D supplements to be taken daily throughout treatment.
Pregnancy and Breastfeeding
Zoledronic acid should not be used during pregnancy. Animal studies have shown reproductive toxicity, including skeletal abnormalities in the developing fetus. If you are pregnant, think you may be pregnant, or are planning to become pregnant, inform your doctor immediately. Because bisphosphonates are incorporated into the bone matrix and released slowly over years, women of childbearing potential should be counseled about the potential risks before starting treatment.
You must not receive zoledronic acid if you are breastfeeding. It is not known whether zoledronic acid passes into human breast milk, but animal data suggest it may. Breastfeeding should be discontinued before treatment begins.
Children and Adolescents
Zoledronic acid is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy in pediatric populations have not been established for the indications described in this article.
Driving and Using Machines
In very rare cases, drowsiness and somnolence have been reported with zoledronic acid use. You should exercise caution when driving, using machines, or performing other activities requiring full concentration. If you experience these effects, avoid driving until symptoms resolve.
How Does Zoledronic Acid Interact with Other Drugs?
Drug interactions with zoledronic acid are clinically important because several commonly used medications can either amplify its effects on calcium levels or increase the risk of kidney damage. It is essential to inform your doctor and pharmacist about all medications you are taking, including prescription drugs, over-the-counter medicines, and supplements. Your healthcare team will review potential interactions before each infusion cycle.
Because zoledronic acid is not metabolized by liver enzymes and is excreted unchanged by the kidneys, traditional pharmacokinetic drug interactions (such as those involving the cytochrome P450 system) are generally not a concern. However, pharmacodynamic interactions — where two drugs have additive or synergistic effects on calcium metabolism or kidney function — are clinically significant and require monitoring.
Major Interactions
| Interacting Drug | Effect | Recommendation |
|---|---|---|
| Aminoglycosides (e.g., gentamicin, tobramycin) | Additive calcium-lowering effect; both drugs can impair kidney function | Use with caution; monitor calcium and renal function closely |
| Calcitonin | Additive hypocalcemic effect — may lower blood calcium excessively | Monitor serum calcium; adjust supplementation as needed |
| Loop diuretics (e.g., furosemide) | Increase urinary calcium excretion; combined effect may cause severe hypocalcemia | Monitor calcium levels; ensure adequate hydration |
| Thalidomide | May increase risk of renal impairment in multiple myeloma patients | Monitor kidney function closely |
| Anti-angiogenic agents (e.g., bevacizumab, sunitinib) | Increased risk of osteonecrosis of the jaw (ONJ) | Dental screening before treatment; avoid invasive dental procedures |
| Other bisphosphonates | Unknown combined effects; potential for excessive bone resorption suppression | Do not use zoledronic acid with other bisphosphonates concurrently |
| Nephrotoxic drugs (e.g., cisplatin, vancomycin) | Increased risk of renal impairment | Monitor renal function closely; ensure adequate hydration |
Minor Interactions
Because zoledronic acid is not metabolized through the liver’s cytochrome P450 enzyme system, it has a relatively low potential for direct pharmacokinetic interactions with most commonly used medications. However, any drug that affects calcium homeostasis — including calcium supplements and vitamin D — should be coordinated with your treatment schedule. Your healthcare team will typically prescribe daily calcium (500 mg) and vitamin D (at least 400 IU) supplementation throughout the course of zoledronic acid therapy, unless blood calcium levels are already elevated due to tumor-induced hypercalcemia.
Inform your doctor about all herbal supplements and nutritional products you are taking, as some (such as high-dose vitamin A supplements) may theoretically influence bone metabolism. Although no significant interactions have been documented with most herbal products, your healthcare provider should have a complete picture of all substances you are taking.
What Is the Correct Dosage of Zoledronic Acid?
Zoledronic acid must only be administered by healthcare professionals experienced with intravenous bisphosphonate therapy. It is given as a drip (infusion) into a vein over at least 15 minutes and must be infused through a separate, dedicated intravenous line. The medication should never be given as a rapid bolus injection, as faster infusion rates significantly increase the risk of kidney damage.
Before each infusion, your doctor will recommend that you drink plenty of water to ensure adequate hydration. This is particularly important for protecting kidney function. Your healthcare team will also check blood tests, including serum creatinine, before each dose to confirm that your kidneys are functioning adequately.
Adults — Bone Metastases
Standard Dose for Bone Metastases
The recommended dose is 4 mg given as an intravenous infusion over at least 15 minutes, repeated every 3 to 4 weeks. Patients should also receive daily supplementation with calcium (500 mg) and vitamin D (at least 400 IU) unless hypercalcemia is being treated.
Adults — Tumor-Induced Hypercalcemia
Standard Dose for TIH
The recommended dose is a single infusion of 4 mg given over at least 15 minutes. Adequate rehydration with normal saline (0.9% sodium chloride) should be ensured before and after the infusion. If serum calcium levels do not normalize or relapse, re-treatment with a second 4 mg dose may be considered after a minimum interval of 7 days.
Dose Adjustments for Kidney Impairment
Patients with mild to moderate renal impairment (creatinine clearance 30–60 ml/min) at baseline require dose reduction. The dose adjustment is made by removing a specified volume from the ready-to-use solution and replacing it with an equal volume of sterile normal saline or 5% glucose solution:
| Creatinine Clearance (ml/min) | Adjusted Dose | Notes |
|---|---|---|
| >60 ml/min | 4.0 mg (full dose) | No adjustment needed |
| 50–60 ml/min | 3.5 mg | Remove 12 ml, replace with 12 ml saline/glucose |
| 40–49 ml/min | 3.3 mg | Remove 18 ml, replace with 18 ml saline/glucose |
| 30–39 ml/min | 3.0 mg | Remove 25 ml, replace with 25 ml saline/glucose |
| <30 ml/min | Not recommended | Insufficient clinical data; use is contraindicated |
Children
Zoledronic acid is not recommended for use in patients under 18 years of age. The safety and efficacy in pediatric populations have not been established for the oncology indications described in this article.
Elderly
No dose adjustment is required based on age alone for patients aged 65 years and older. However, as kidney function often declines with age, it is especially important that renal function is assessed before each infusion in elderly patients. The dose should be adjusted according to the creatinine clearance values shown above if kidney impairment is present.
Missed Dose
If you miss a scheduled infusion appointment, contact your healthcare provider as soon as possible to reschedule. The treatment regimen will be adjusted to maintain the recommended interval between infusions (every 3–4 weeks for bone metastases). Do not receive a double dose to compensate for a missed infusion.
Overdose
If a dose higher than recommended has been administered, you must be carefully monitored by your healthcare team. Overdose may result in electrolyte abnormalities — particularly low levels of calcium (hypocalcemia), phosphorus (hypophosphatemia), and magnesium (hypomagnesemia) — as well as kidney function deterioration, including severe renal impairment. If calcium levels drop too low, intravenous calcium gluconate may be required. There is no specific antidote for zoledronic acid overdose; treatment is supportive and directed at correcting electrolyte imbalances and maintaining kidney function.
What Are the Side Effects of Zoledronic Acid?
Like all medicines, zoledronic acid can cause side effects, although not everybody experiences them. The most common side effects are generally mild and tend to occur within the first 1–3 days after infusion, particularly after the first dose. These “acute-phase reactions” (flu-like symptoms) typically diminish with subsequent infusions as the body becomes accustomed to the medication.
The following side effects are organized by frequency, from most to least common. If you experience any side effects that concern you, or if symptoms are severe or persistent, contact your healthcare provider promptly.
Very Common
May affect more than 1 in 10 people
- Low blood phosphate levels (hypophosphatemia)
Common
May affect up to 1 in 10 people
- Headache and flu-like syndrome (fever, fatigue, weakness, drowsiness, chills, bone, joint and/or muscle pain)
- Gastrointestinal reactions (nausea, vomiting, loss of appetite)
- Conjunctivitis (eye inflammation)
- Anemia (low red blood cell count)
- Low blood calcium levels (hypocalcemia)
- Severe kidney impairment (detected by blood tests)
Uncommon
May affect up to 1 in 100 people
- Osteonecrosis of the jaw (ONJ) — pain, swelling, non-healing sores in the mouth, loose teeth
- Atrial fibrillation (irregular heartbeat)
- Severe allergic reaction (difficulty breathing, facial/throat swelling)
- Hypersensitivity reactions, low blood pressure, chest pain
- Skin reactions (redness, swelling) at the infusion site, rash, itching
- High blood pressure, shortness of breath, dizziness, anxiety, sleep disturbance
- Taste changes, tremor, tingling/numbness in hands and feet
- Diarrhea, constipation, abdominal pain, dry mouth
- Low white blood cell and platelet counts
- Low blood magnesium and potassium levels
- Weight gain, increased sweating, drowsiness
- Blurred vision, watery eyes, light sensitivity
- Hives (urticaria)
Rare
May affect up to 1 in 1,000 people
- Cardiac arrhythmia (due to severe hypocalcemia)
- Fanconi syndrome (a kidney disorder detected by urine tests)
- Slow heart rate (bradycardia)
- Confusion
- Atypical femoral fractures (unusual fractures in the thigh bone)
- Interstitial lung disease
- Painful red and/or swollen eyes (uveitis, episcleritis)
Very Rare
May affect up to 1 in 10,000 people
- Seizures, numbness, and twitching (tetany, due to severe hypocalcemia)
- Bone damage in the ear (osteonecrosis) — ear pain, discharge, ear infection
- Osteonecrosis in bones other than the jaw (hip, femur)
- Fainting due to low blood pressure
- Severe, incapacitating bone, joint, and/or muscle pain
Contact your doctor immediately if you experience any of the following: severe jaw pain or swelling, non-healing sores in the mouth, significant decrease in urine output, blood in urine, severe bone/muscle pain, signs of severe allergic reaction (difficulty breathing, facial swelling), irregular heartbeat, or seizures. These may indicate serious side effects requiring prompt medical evaluation.
How Should Zoledronic Acid Be Stored?
Because zoledronic acid is administered by healthcare professionals in hospital or clinic settings, storage is typically handled by your medical team rather than at home. However, understanding proper storage conditions is important for ensuring medication quality and safety:
- Unopened vials/bottles: No special storage conditions are required. Store at room temperature.
- After opening: Chemical and physical in-use stability has been demonstrated for 24 hours at 2–8°C and at 25°C. From a microbiological standpoint, the solution should be used immediately after opening.
- If not used immediately: The solution may be stored at 2–8°C for up to 24 hours. Refrigerated solutions should be allowed to reach room temperature before administration.
- Single use only: Any unused solution must be discarded. Only clear, particle-free, and uncolored solutions should be used.
Keep this medicine out of the sight and reach of children. Do not use after the expiry date stated on the carton and vial label (after EXP). The expiry date refers to the last day of that month. Do not dispose of medicines via household waste or wastewater — ask your pharmacist how to properly dispose of medicines no longer required to help protect the environment.
What Does Zoledronsyra STADA Contain?
Understanding the composition of your medication is important, particularly if you have known allergies to any pharmaceutical excipients. Zoledronsyra STADA is a clear, colorless solution free from visible particles, supplied in glass or plastic vials or polypropylene bags.
Active Ingredient
- Zoledronic acid — 4 mg per vial (equivalent to 4.26 mg zoledronic acid monohydrate)
Inactive Ingredients (Excipients)
- Mannitol (E421) — a sugar alcohol used as a stabilizer and tonicity agent
- Sodium citrate (E331) — a buffering agent to maintain the correct pH of the solution
- Water for injections — the solvent
This medicine contains less than 1 mmol sodium (23 mg) per 100 ml infusion, meaning it is essentially sodium-free. This is important information for patients on a controlled sodium diet.
Available Pack Sizes
Zoledronsyra STADA is available in packs containing 1 or 4 vials, or 1 or 4 bags. Not all pack sizes may be marketed in all countries. The medication is manufactured by STADA Arzneimittel AG, Bad Vilbel, Germany, among other approved manufacturing sites.
Frequently Asked Questions About Zoledronic Acid
Zoledronic acid (Zoledronsyra STADA) is a potent bisphosphonate given intravenously. The 4 mg formulation is used in oncology to prevent skeletal complications (fractures, spinal cord compression, need for bone radiation/surgery) in adults with bone metastases from solid tumors, and to reduce dangerously elevated blood calcium levels caused by malignancy (tumor-induced hypercalcemia). A separate 5 mg annual infusion formulation is used for osteoporosis and Paget’s disease.
Zoledronic acid is given as an intravenous (IV) drip over at least 15 minutes through a dedicated IV line. It must be administered by trained healthcare professionals in a clinical setting. Patients should be well hydrated before and after the infusion. The standard dose for bone metastases is 4 mg every 3–4 weeks. The solution must not be mixed with other infusion solutions or medications.
The most common side effects include flu-like symptoms such as fever, fatigue, bone and muscle pain, and chills, which typically occur within 1–3 days after infusion and usually resolve on their own. Other common effects include low blood phosphate levels, nausea, headache, anemia, and conjunctivitis. These acute-phase reactions tend to be most pronounced after the first infusion and diminish with subsequent treatments.
Yes, kidney impairment is a recognized side effect of zoledronic acid. The risk is higher if the infusion is administered too quickly (faster than 15 minutes) or if the patient is dehydrated. Your doctor will monitor your kidney function (serum creatinine) before each infusion. Patients with severe kidney impairment (creatinine clearance below 30 ml/min) should not receive this medication. Dose reductions are required for patients with mild to moderate impairment.
Osteonecrosis of the jaw (ONJ) is a condition where bone tissue in the jaw fails to heal, leading to exposed bone, pain, swelling, and potential infection. It is classified as an uncommon side effect (affecting up to 1 in 100 patients). Risk factors include dental surgery, poor oral hygiene, concurrent chemotherapy or corticosteroid use, cancer, and smoking. A dental check-up before starting treatment and maintaining good oral hygiene throughout therapy can help reduce this risk.
All information is based on international medical guidelines and peer-reviewed research: EMA Summary of Product Characteristics for zoledronic acid, FDA prescribing information, ASCO Clinical Practice Guidelines on the role of bone-modifying agents in metastatic cancer, ESMO Clinical Practice Guidelines for management of bone metastases, and WHO Model List of Essential Medicines. All medical claims have evidence level 1A based on systematic reviews and randomized controlled trials.
- European Medicines Agency (EMA). Summary of Product Characteristics: Zoledronic acid. Last updated 2025.
- U.S. Food and Drug Administration (FDA). Zoledronic acid prescribing information. Available at: fda.gov.
- Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors. Cancer. 2004;100(12):2613–2621.
- Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer. J Clin Oncol. 2005;23(15):3314–3321.
- Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011;29(9):1221–1227.
- Coleman R, Body JJ, Aapro M, et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31(12):1650–1663.
- World Health Organization. WHO Model List of Essential Medicines. 23rd List, 2023.
- Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3–23.
Editorial Team
Medical Review
This article has been reviewed by the iMedic Medical Review Board, a team of licensed specialist physicians in clinical pharmacology, oncology, and bone metabolism. All content follows the GRADE evidence framework and adheres to international guidelines from the WHO, EMA, FDA, ASCO, and ESMO.
Editorial Standards
iMedic maintains strict editorial independence with no commercial funding or pharmaceutical industry sponsorship. All medical claims are supported by peer-reviewed evidence at the highest available level. Content is regularly updated to reflect new guidelines and safety information. Read our editorial standards.